Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Santen Bags Global Rights to Aerie’s Glaucoma Meds, Except US, in Expanded Pact
Santen Pharmaceutical said on December 7 that it has signed a deal to extend the reach of its exclusive license for two glaucoma drugs of US ophthalmology specialist Aerie Pharmaceuticals, grabbing the rights to develop and commercialize them worldwide, excluding…
To read the full story
Related Article
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
- Santen’s Glaucoma Med Rhopressa Hits Shelves in South Korea
November 5, 2024
- Santen Gets Asian Rights to Aerie’s Glaucoma Meds
October 29, 2020
BUSINESS
- ASKA Set to Seek Shareholder OK for Faster Poison Pill Activation
May 27, 2026
- Eylea Biosimilar Shipment Restrictions to Be Lifted on June 5
May 27, 2026
- Bayer’s Low-Dose MRI Contrast Agent Ambelvist Debuts in Japan
May 27, 2026
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…